To the Editor: Although seasonal patterns of pediatric alopecia areata (AA), totalis (AT), and universalis (AU) have been suspected clinically, there is limited research about whether disease flares follow a temporal pattern. [1] [2] [3] Patients and families report increased hair loss during the winter, with cycles of regrowth in summer months. Through retrospective review of medical records, we sought to identify whether AA, AT, and AU flares show seasonal variation in pediatric patients and to characterize temporal patterns.
The medical records of 457 children with AA, AT, or AU diagnoses were reviewed; 336 children met criteria for inclusion, with month of onset of either the initial or a subsequent flare documented. AU patients with no documented flares before complete scalp hair loss (ie, Severity of Alopecia Tool score of 100) were excluded. We recorded demographic data, patient-reported month of flare ( for up to 2 flares including the initial episode), final diagnosis (AA, AT, or AU), skin type, history of atopy, and patient-reported race/ethnicity. History of atopy was considered positive if any of the following were documented: atopic dermatitis, asthma, allergic rhinitis, eosinophilic esophagitis, or anaphylactic food allergy. Flares were defined as an increase in scalp hair loss noted by the patient or caregiver. To limit the confounding effect of steroids, increased hair loss occurring immediately after a course of oral steroids was not considered a flare. Summary statistics were performed using STATA/IC version 15.1.
The male-to-female ratio was 1:1.5. Roughly half (52.2%) of our sample self-reported as white, 19.6% black, 8.9% other, 8.9% Hispanic or Latino, 4.1% Asian, 3.9% Indian, and \3% unknown. Most of the population (73.5%) had a diagnosis of AA, 13.7% AT, and 12.8% AU. Over half (63.8%) of patients had a documented history of atopy (87 atopic dermatitis, 47 allergic rhinitis, 35 asthma, 14 anaphylactic food allergy, 2 eosinophilic esophagitis).
Of 518 total flares (Fig 1) , the greatest proportion occurred in November (11.4%), followed by October (11.0%) and January (10.2%). Months with the lowest proportion of flares included May (3.5%) and August (5.6%). In patients with a history of atopy (Fig 2) , who had a total of 198 flares, the frequency of flares was highest in March (14%) and November (13%). In patients without a history of atopic (Fig 2) , who had a total of 320 flares, frequency of flares was highest in October (13%).
This study provides insight into the natural history of AA. Environmental triggers for autoimmune alopecia have not been identified, and our results suggest that there might be a seasonal pattern, a predilection for flares during colder months; to what degree remains unclear. In AA patients with atopy or historically cyclic flare patterns, it may be reasonable to recommend prophylactic antihistamine therapy during high-risk flare months. Evidence supporting antihistamine therapy for AA is limited, but by inhibiting T-cell migration and T-helper 2etype cytokine production, these medications might interfere with CD4 1 T-celle driven inflammation that contributes to hair follicle destruction in AA. 4, 5 Our study is limited by its retrospective design, patient recall, and a small sample size. To better identify seasonal flare patterns, future studies should aim for larger samples. Reprints not available from the authors. To the Editor: Nail examinations present opportunities to diagnose nail unit malignancies, including squamous cell carcinomas and melanomas, in their earliest stages, thus potentially avoiding amputations and/or prolonging life. 1,2 A survey-based study of patients' knowledge of longitudinal melanonychia and warning signs of subungual melanoma found that patients' knowledge was very limited, with only 31% of participants examining their nails regularly and 12% of subjects stating that their physician (dermatologist or internist in an outpatient setting) asked them about nail changes. 3 Our study aimed to assess patients' knowledge of the components of a complete skin examination, specifically, nail examinations.
After the Weill Cornell Institutional Review Board deemed the study exempt, we performed a survey-based study at the American Academy of Dermatology (AAD) free skin cancer screening at Weill Cornell Medicine on May 11, 2018. Screeners were instructed to perform a full body screen, including examination of the scalp and nails. Because of the volume of patients, nail polish 
